Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA

NCT ID: NCT02351011

Last Updated: 2019-09-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-28
• Study Completion Date: 2018-12-31

Brief Summary

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a lasting condition in which the material that cushions the joints, called cartilage, breaks down. This causes the bones to rub against each other, causing inflammation, stiffness, pain and loss of joint movement. Currently, there are few effective treatments available for patients suffering from OA.

Mesenchymal stem cells (MSCs) are cells that have the ability to self-regenerate, which means they have the ability to make copies of themselves and to turn into other kinds of cells (e.g. cartilage cells). Stem cell science shows much promise for the future treatment of osteoarthritis, but much of the research is still in the early stages. In this study, researchers want to determine the safety of MSCs that a patient can tolerate without causing side effects. This will be done by starting at a low dose of MSCs and moving on to the next higher dose level provided there are no safety concerns. Researchers will also be looking at the function of the knee over time, which may give them some insight on the usefulness of MSCs as a treatment option.

Detailed Description

The trial is a non-randomized, open-label, dose escalation phase I/II clinical trial. A total of 12 participants will be enrolled - patients will be treated in cohorts of 3 to determine the safety and preliminary efficacy of autologous, ex-vivo expanded bone-marrow derived MSC injected into the knee joint in patients with moderate to advanced knee osteoarthritis.

A minimum of three evaluable patients will be entered at each dose level until the maximum tolerated dose (MTD) is reached. Toxicity will be evaluated and graded according to the Common Terminology Criteria (CTC) for Adverse Events, as Grade 3-4. If a patient is discontinued due to a grade 3 or 4 adverse event (i.e. dose-limiting toxicity, DLT), an additional patient will be enrolled at the same dose level to ensure that a minimum of 3 patients are evaluated. If 0/3 patients experience dose-limiting (DLT) at a given dose level, then the dose will be escalated for next cohort of 3 patients. If 1/3 patients experience DLT at a given dose level, then an additional 3 patients will be treated at that dose level. If no other patient experiences a DLT, dose escalation will continue. If DLT occurs in 2/3 or 2/6 patients, dose escalation will stop and the prior dose level will be declared the MTD for the MSC cell infusions in this study.

Conditions

Osteoarthritis of Knee

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Cohort 1

1 x 10\^6 MSCs

Group Type: EXPERIMENTAL

1 x 10^6 MSCs

Intervention Type: BIOLOGICAL

Autologous, bone-marrow derived MSCs

Cohort 2

10 x 10\^6 MSCs

Group Type: EXPERIMENTAL

10 x 10^6 MSCs

Intervention Type: BIOLOGICAL

Autologous, bone-marrow derived MSCs

Cohort 3

50 x 10\^6 MSCs

Group Type: EXPERIMENTAL

50 x 10^6 MSCs

Intervention Type: BIOLOGICAL

Autologous, bone-marrow derived MSCs

Interventions

1 x 10^6 MSCs

Autologous, bone-marrow derived MSCs

Intervention Type: BIOLOGICAL

10 x 10^6 MSCs

Autologous, bone-marrow derived MSCs

Intervention Type: BIOLOGICAL

50 x 10^6 MSCs

Autologous, bone-marrow derived MSCs

Intervention Type: BIOLOGICAL

Other Intervention Names

Mesenchymal Stromal Cells (MSCs); Mesenchymal Stromal Cells (MSCs); Mesenchymal Stromal Cells (MSCs)

Eligibility Criteria

Inclusion Criteria

1. Patients between 40-65 years of age with symptomatic moderate to severe (Kellgren-Lawrence III or IV) primary osteoarthritis of the knee

2. Failed conservative management including physical therapy, bracing and/or oral anti-inflammatories for a minimum of six months

3. No history of prior intra-articular cortisone, hyaluronic acid, or platelet-rich plasma injection within the previous six months

4. No history of prior arthroscopic knee surgery or open knee surgery on the ipsilateral side within the past year

5. Adequate bone marrow, liver, and renal functions

6. Body weight >40 kg

7. Body Mass Index <30

8. Negative for (HIV, HTLV1&2, Hep A, B, C, syphilis) infection as determined by approved serological testing

9. Negative for pregnancy as determined by a serum pregnancy test. Females of childbearing potential will be required to practice abstinence or use an effective form of contraception for 12 months following their MSC injection.

10. Fluid > 1 cm within the lateral recess of the suprapatellar pouch at the level of the superior pole of the patella with the knee extended.

Exclusion Criteria

1. Patients with clinically unstable knee due to the presence of a complete anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament and/or posterolateral corner tear

2. Patients with varus or valgus malalignment >5 degrees as measured by 4 foot standing antero-posterior radiographs

3. Patients with a history of a previous subtotal medial or lateral meniscectomy

4. Patients with a history of septic arthritis in the affected joint

5. Patients with a history of a prior intra-articular knee fracture

6. Severe bleeding diathesis

7. Contraindication to bone marrow aspiration and/or biopsy

8. Active infection

9. Bone marrow failure

10. Cytopenia

11. Patients who have previously received radiotherapy to the pelvis

12. Patients who have been on chemotherapy from within a year of the date of informed

13. Patients with positive serological test for (HIV, HTLV1&2, Hep A, B, C, syphilis)

14. Pregnancy or risk of pregnancy (this includes participants that are not willing to practice active contraception for the duration of the study)

15. Patients with unforeseen conditions that are deemed unsafe or inappropriate for the study (e.g. patients who are claustrophobic and cannot undergo an MRI) as per the discretion of the principal investigator

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jas Chahal

OTHER

Sponsor Role: lead

Responsible Party

Jas Chahal

Orthopaedic Surgeon

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jas Chahal, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Arthritis Program, Toronto Western Hospital

Sowmya Viswanathan, PhD

Role: PRINCIPAL_INVESTIGATOR

Arthritis Program, Toronto Western Hospital & Philip S. Orsino Facility for Cell Therapy

Locations

Toronto Western Hospital

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

MSC-001

Identifier Type: -

Identifier Source: org_study_id